Biotech Values

[jq1234]

Mind if I ask why you like CLDX when Pfizer decided to drop their lead drug.

Look, CLDX has market cap of $130m, enterprise value under $90m. Find me another one with similar valuation and drug candidates (two candidates CDX110 and CDX011 with well defined targets). I looked at the data that had been very consistent, not what PFE did. I liked EXEL when BMY dropped XL184, I liked IMGN when FDA refused to file TDM-1 for 3rd line BC. Those were times that presented most value. I call those events as negative news without change of fundamental because I focus on data. If data were bad, then fundamental had changed. Sure they might need to raise money at some point, that is what developing stage biotechs do. Enter when valuation is low, don't worry about dilution that much. Those who follow the trend enter when the valuation is high, then complain about dilution.